Inicio › Linfoma de Burkitt › Ohio

Ensayos clínicos de Linfoma de Burkitt en Ohio

17 estudios sobre Linfoma de Burkitt buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Center-West Chester, West Chester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT03739814

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 3 más

ReclutandoFase 2

366 Days – 46 Years · Todos los sexos · Actualizado el 28 sept 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 2 más

ReclutandoFase 2

365 Days · Todos los sexos · Actualizado el 25 sept 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

University of Cincinnati Medical Center, Cincinnati

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati

ReclutandoFase 3

Edades de 1 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07223021

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
y 2 más

ReclutandoFase 3

Edades de 18 a 39 · Todos los sexos · Actualizado el 2 sept 2026 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 3 más

ReclutandoFase 2

Edades de 1 a 30 · Todos los sexos · Actualizado el 1 sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 4 más

ReclutandoFase 3

365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoFase 2

Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

The Ohio State University Wexner Medical Center, Columbus

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoEstudio observacional

Edades de 0 a 38 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06131801

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital, Columbus
Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 1

Edades de 2 en adelante · Todos los sexos · Actualizado el 29 may 2026 · NCT05418088

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Cleveland Clinic Foundation, Cleveland

ReclutandoFase 2

Edades de 18 a 54 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06918431

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoFase 1

Edades de 1 a 39 · Todos los sexos · Actualizado el 18 feb 2026 · NCT06863259

Study of SGR-1505 in Mature B-Cell Neoplasms

Gabrail Cancer & Research Center, Canton
The Ohio State University - The James Cancer Hospital, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Cleveland Clinic, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

University of Cincinnati, Cincinnati

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 nov 2024 · NCT06034275

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.